Table 1.
Selected patient characteristics at baseline, overall and stratified by switching status
| Variable | Overall N = 14,729 |
Non-switchers N = 13,734 |
Switchers N = 995 |
Standardized difference |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Age, mean (SD) | 53.2 (14.3) | 53.3 (14.4) | 52.0 (13.7) | 0.091 |
| Median (Q1, Q3) | 54.0 (43.0, 64.0) | 54.0 (43.0, 64.0) | 53.0 (43.0, 62.0) | |
| Female, n (%) | 6714 (45.6) | 6196 (45.1) | 518 (52.1) | 0.035 |
| Race, n (%a) | 0.030 | |||
| White | 11,648 (79.2) | 10,894 (79.4) | 754 (75.9) | |
| Black | 543 (3.7) | 489 (3.6) | 54 (5.4) | |
| Asian | 1485 (10.1) | 1382 (10.1) | 103 (10.4) | |
| Other | 1031 (7.) | 948 (6.9) | 83 (8.4) | |
| Ethnicity (Hispanic), n (%) | 1521 (10.5) | 1419 (10.5) | 102 (10.4) | 0.001 |
| Employment (full time), n (%) | 8645 (58.9) | 8070 (59.0) | 575 (58.1) | 0.005 |
| Year of baseline visit, n (%) | 0.029 | |||
| 2019 | 1848 (12.5) | 1689 (12.3) | 159 (16.0) | |
| 2020 | 4231 (28.7) | 3944 (28.7) | 287 (28.8) | |
| 2021 | 4571 (31.0) | 4277 (31.1) | 294 (29.5) | |
| 2022 | 4079 (27.7) | 3824 (27.8) | 255 (25.6) | |
| Baseline medication class, n (%) | 0.078 | |||
| TNFi | 1770 (12.0) | 1602 (11.7) | 168 (16.9) | |
| IL-17i | 5414 (36.8) | 4959 (36.1) | 445 (44.7) | |
| IL-23i | 5797 (39.4) | 5541 (40.3) | 256 (25.7) | |
| Other | 1758 (11.9) | 1632 (11.9) | 126 (12.7) | |
| Disease characteristics | ||||
| Psoriatic arthritis, n (%) | 6274 (42.9) | 5758 (42.2) | 516 (52.1) | 0.050 |
| BSA (% involvement), mean (SD) | 1.8 (4.4) | 1.6 (4.1) | 3.8 (7.1) | 0.498 |
| Median (Q1, Q3) | 1.0 (0.0, 2.0) | 1.0 (0.0, 1.8) | 2.0 (0.0, 5.0) | |
| Mild disease (< 3%), n (%) | 12,152 (82.5) | 11,542 (84.0) | 610 (61.3) | 0.155 |
| Moderate disease (3–10%), n (%) | 2225 (15.1) | 1,914 (13.9) | 311 (31.3) | |
| Severe disease (> 10%), n (%) | 352 (2.4) | 278 (2.0) | 74 (7.4) | |
| At least 1 prior biologic therapy, n (%) | 1815 (12.3) | 1647 (12.0) | 168 (16.9) | 0.024 |
| Duration of biologic therapy at baseline | 0.064 | |||
| 5 to < 12 months, n (%) | 5046 (34.3) | 4595 (33.5) | 451 (45.3) | |
| 12 to < 24 months, n (%) | 5045 (34.3) | 4740 (34.5) | 305 (30.7) | |
| 24+ months, n (%) | 4638 (31.5) | 4399 (32.0) | 239 (24.0) | |
| Number of prior NBSM, mean (SD) | 0.1 (0.4) | 0.1 (0.4) | 0.2 (0.5) | 0.148 |
| Median (Q1, Q3) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | |
| NBSM addedb, n (%) | 83 (0.6) | 56 (0.4) | 27 (2.7) | 0.077 |
| Number of prior topical therapies, mean (SD) | 1.2 (2.0) | 1.2 (1.9) | 1.6 (2.2) | 0.179 |
| Median (Q1, Q3) | 0.0 (0.0, 3.0) | 0.0 (0.0, 3.0) | 0.0 (0.0, 3.0) | |
| Patient-reported outcomes | ||||
| Patient global assessment, mean (SD) | 15.1 (22.7) | 14.3 (22.2) | 25.9 (26.5) | 0.517 |
| Median (Q1, Q3) | 5.0 (0.0, 20.0) | 5.0 (0.0, 15.0) | 15.0 (5.0, 40.0) | |
| DLQI, mean (SD) | 1.9 (3.2) | 1.7 (3.0) | 3.5 (4.5) | 0.560 |
| Median (Q1, Q3) | 1.0 (0.0, 2.0) | 1.0 (0.0, 2.0) | 2.0 (1.0, 5.0) | |
| Fatigue, mean (SD) | 18.6 (24.2) | 18.0 (23.8) | 27.0 (27.2) | 0.372 |
| Median (Q1, Q3) | 7.0 (0.0, 30.0) | 5.0 (0.0, 25.0) | 20.0 (4.0, 50.0) | |
| Itch/pruritus, mean (SD) | 13.6 (22.2) | 12.8 (21.5) | 24.5 (28.5) | 0.531 |
| Median (Q1, Q3) | 5.0 (0.0, 15.0) | 5.0 (0.0, 15.0) | 10.0 (2.8, 40.0) | |
| EQ-5D, mean (SD) | 80.2 (17.9) | 80.6 (17.8) | 75.1 (18.9) | 0.306 |
| Median (Q1, Q3) | 85.0 (75.0, 90.0) | 85.0 (75.0, 91.0) | 80.0 (70.0, 90.0) | |
BSA body surface area, DLQI Dermatology Life Quality Index, EQ-5D EuroQOL Five Dimensions Questionnaire, IL-17i interleukin-17 inhibitor, IL-23i interleukin-23 inhibitor, NBSM non-biologic systemic medication, Q1 1st quartile, Q3 3rd quartile, SD standard deviation, TNFi tumor necrosis factor inhibitor
aPercentages are among those with non-missing values. Percentages may not sum to 100 due to rounding
bMeasures from baseline to follow-up do not include the status at the endpoints. That is, they measure changes between the 2 registry visits, not including those occurring at the given visits